OrthoPediatrics Corp.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US68752L1008
USD
18.17
0.47 (2.66%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About OrthoPediatrics Corp. stock-summary
stock-summary
OrthoPediatrics Corp.
Pharmaceuticals & Biotechnology
OrthoPediatrics Corp. is a medical device company focused on providing product offerings to the pediatric orthopedic market for children with orthopedic conditions. The Company designs, develops and commercializes orthopedic implants and instruments to meet the specialized needs of pediatric surgeons and their patients. The Company operates through the OrthoPediatrics segment, which designs, develops and markets implants and devices for children with orthopedic problems. Its products include RESPONSE Spinal Deformity System, PediNail Intramedullary Nail System, PediLoc Plating Systems, ACL Reconstruction System, Cannulated Screws, Locking Cannulated Blade (LCB) plate system, Locking Proximal Femur (LPF) plate system, PediFlex Flexible Nailing System, PediFrag, PediLoc Extension Osteotomy Plate (PLEO), PediLoc Femur Locking Plate System, PediLoc Tibia Locking Plate System, PediPlates system and Spica Table.
Company Coordinates stock-summary
Company Details
2850 Frontier Dr , WARSAW IN : 46582-7001
stock-summary
Tel: 1 574 26863791 646 5367035
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 39 Schemes (25.34%)

Foreign Institutions

Held by 64 Foreign Institutions (6.43%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Terry Schlotterback
Independent Chairman of the Board
Mr. Mark Throdahl
Chief Executive Officer, Director
Mr. Fred Hite
Chief Financial Officer, Chief Operating Officer, Director
Mr. David Pelizzon
Director
Mr. Harald Ruf
Director
Mr. Bernie Berry
Independent Director
Mr. Stephen Burns
Independent Director
Mr. Bryan Hughes
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
61 Million
(Quarterly Results - Jun 2025)
Net Profit:
-7 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 524 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.07

stock-summary
Return on Equity

-8.45%

stock-summary
Price to Book

1.47